5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

CAHR Market Access 201 Conference Update – November 2020

December 1, 2020
-
Market Access News
-
Posted by MORSE - 4 min read.
COVID-19, HTA, PMPRB, RWE, Market Access, Drug Reimbursement

Introduction

 

The Canadian Association for Healthcare Reimbursement (CAHR) held its first virtual Market Access 201 conference on November 24, 2020.  Members of the MORSE team attended this conference and have prepared a brief summary of the key highlights.

Disclaimer: Please note, this summary is based on our team’s interpretation of the discussion.

 

Session 1. Keynote: Evolution of HTA in United States and the Impact on International Markets

 

Speaker: Dr. Dan Ollendorf, Director of Value Measurement & Global Health Initiatives at CEVR

Moderator: Tarry Ahuja, Manager – Program Development Pharmaceutical Reviews & RWE Advisor at CADTH

“ICER has raised awareness and filled an HTA ‘void’ in the US”

In this keynote, Dr. Dan Ollendorf delineated the history of the US using cost-effectiveness as a tool for decision making. He started by explaining the initial Office of Technology Assessment (OTA), and went on to describe the Agency for Healthcare Research & Quality (AHRQ), and the Patient-Centered Outcomes Research Institute (PCORI), and finally to the current Institute for Clinical and Economic Review (ICER). With the recent political and social changes affecting ICER and HTA in the US, he anticipated limitations in international market access as well as reduced prices as a result of changes in reference pricing.

 

Session 2. Panel: Operationalizing of Proposed PMPRB Guidelines: A Global Perspective

 

Speakers: Joan McCormick, Principal at IQVIA;

Chris Cameron, Senior Vice President, Data Analytics & Evidence Synthesis at EVERSANA;

Heather McDonald, Global Vice President and Head, Pricing Innovation and Implementation at Bayer Pharmaceuticals

Moderator: Kimberly Robinson, Director, Pricing and Market Access at PDCI Market Access Inc.

“Are we solving the correct problem with the correct tools? … (we should) use our collective expertise to allow patient access to cutting edge healthcare technologies…”

In the panel on operationalizing of proposed PMPRB guidelines, Joan McCormick spoke to the new PMPRB rules and the current court challenges on this subject. She described how these challenges may potentially impact the future PMPRB framework. She also gave the audience an overview of the modernization process that the PMPRB has promised to deliver. Chris Cameron then provided his perspective as a former HTA reviewer, highlighting that cost-effectiveness analysis and market size analysis will become more pivotal in pricing for Category 1 drugs for both public and private payers. Finally, Heather McDonald offered a global perspective on the new PMPRB guidelines. She commented on the PMPRB reforms and how they have introduced a great deal of uncertainty and unpredictability for manufacturers looking to enter the Canadian market, emphasizing that the reforms may restrict access to innovative health technologies for Canadians.

 

Session 3. Panel: Global Health Technology Assessment: Where Does Canada Fit?

 

Speakers: Jason Flavin, Global Senior Health Economics and Outcomes Research Manager at Boehringer Ingelheim;

Demitri Diles, Access Lead of Neuroimmunology at Roche

Moderator: Tarry Ahuja, Manager – Program Development Pharmaceutical Reviews & RWE Advisor at CADTH

“Canadian team needs to work closely with Global to proactively plan for potential requests/issues during the review”

From a global perspective, Jason Flavin discussed the different HTA requirements across countries, including clinically driven HTA in Germany, cost-effectiveness driven HTA in Canada, as well as budget impact driven HTA in China. He commented that global differences in HTA have decreased due to common challenges and increased collaboration between HTA/reimbursement agencies. He also spoke to the complexity of international price referencing across different reference countries, methodologies and types of reference prices. Demitri Diles then offered a Canadian perspective on HTA, showing that Canadian Market Access teams need to work closely with their Global Market Access team to proactively plan to address common inquiries from Canadian HTA agencies including clinical protocol and efficacy, real world data, regulatory affairs, and pharmacoeconomics. In a challenging reimbursement climate, such as this one, early engagement with Global Market Access teams are crucial to facilitate the reimbursement process from start to finish.

 

Session 4. Keynote: Role of Real-World Data (RWD) & Artificial Intelligence and Global Market Access

 

Speaker: Dr. Brigham Hyde, President, Data & Analytics at EVERSANA

Moderator: Tarry Ahuja, Manager – Program Development Pharmaceutical Reviews & RWE Advisor at CADTH

“RWD models will be disruptive to traditional clinical research models and economics”

Dr. Brigham Hyde spoke to how RWD can help address unmet needs in the market access landscape and confront healthcare challenges such as targeted and complex therapies, and value-based contracting. Further, he recognized the shortcomings of using RWD in decision making including the lack of standardization and implicit bias in data collection, which could be mitigated by expert human curation and meticulous audit.

 

Session 5. Keynote: Harmonizing Real World Datasets to Maximize Value in Global Research & Development, and Market Access

 

Speaker: Dr. Kim Van Naarden Braun, Associate Director, Translational Epidemiology at Bristol Myers Squibb

Moderator: Tarry Ahuja, Manager – Program Development Pharmaceutical Reviews & RWE Advisor at CADTH

“Real-World Data (RWD) are data relating to patient health status and/or delivery of health care routinely collected from a variety of sources.”
“Real-World Evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from Real World Data.”

In this keynote, Dr. Kim Van Naarden Braun started by emphasizing that the types and sources of RWD are highly diverse. She went on to explain that RWD harmonization is required to achieve adequate sample size and increase heterogeneity of patient populations. Once harmonized, the data can then be utilized to inform market access considerations. She cautioned that the potential of RWD should be harnessed with the overarching consideration that RWD needs to be ‘fit for purpose’ with transparent and defensible reliability, validity, and relevance.

 

Session 6. Panel: Budgetary Pressures in a Post-COVID World. Perspective from HTA and Payers and Industry

 

Speakers: Kevin Leshuk, Pharmaceutical Executive at Forus Group;

Dr. Trevor Richter, Director, Pharmaceutical Reviews at CADTH

Moderator: Ferg Mills, Director, Strategic Consulting at Innomar Strategies

“Canada is under huge budgetary pressure due to the pandemic”

In this panel discussion on Budgetary Pressures in a Post-COVID World, Kevin Leshuk from the Forus Group and Dr. Trevor Richter from CADTH provided their perspectives from industry and HTA, respectively. They highlighted the unprecedented nature of the current budgetary challenge. Kevin Leshuk discussed the decline in drug development and clinical trials for manufacturers, while Dr. Trevor Richter expressed optimism in drug review programs which have continued to meet previous metrics despite the COVID-19 pandemic. They subsequently spoke to topics including stakeholder engagement, prioritization of treatments and populations at risk, and the assessment of value & acceptance of uncertainty.
 
 

Share
Tags
CAHR
COVID-19
Drug Manufacturer
HTA
ICER
Market Access Strategy
pCPA
pCPAO
Pharmacare
PMPRB
Public Payers
Reimbursement strategy
RWD
← PREVIOUS POST
pCPA Under Consideration Backlog Starting to Form
NEXT POST →
pCPA Activity increases in October 2020

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
CAHR Market Access 201 Conference Update - November 2020